rs1801690 — APOH Trp316Ser

Missense variant in APOH (beta-2-glycoprotein I) that disrupts the phospholipid-binding domain, reducing the protein's capacity to act as an autoantigen in antiphospholipid syndrome

See your personal result for APOH

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

APOH Trp316Ser — The Phospholipid Lock That Opens the Door to Antiphospholipid Syndrome

Beta-2-glycoprotein I (β2GPI)11 Beta-2-glycoprotein I (β2GPI)
β2GPI, encoded by APOH on chromosome 17, is a 50 kDa plasma protein that circulates at 200 µg/mL and binds avidly to anionic phospholipid surfaces exposed on activated platelets and apoptotic cells is the primary autoantigen in antiphospholipid syndrome (APS), an acquired autoimmune thrombophilia that is among the most common causes of recurrent venous thromboembolism and pregnancy loss. The variant rs1801690 changes a tryptophan to serine at position 316 of the APOH protein — precisely within the hydrophobic cluster that anchors β2GPI to phospholipid membranes. Whether you carry this change determines how efficiently your β2GPI binds phospholipids, and by extension, how likely it is to become an autoantigen that drives thrombosis.

The Mechanism

Beta-2-glycoprotein I contains five complement-control protein domains. Domain V is the phospholipid-binding domain, featuring a short hydrophobic loop and a conserved lysine-rich cluster22 lysine-rich cluster
Positively charged lysines bind the negatively charged phospholipid head groups; the hydrophobic loop inserts into the membrane bilayer to anchor the protein. Flanking this loop is a four-residue sequence at positions 313–316 (Leu-Ala-Phe-Trp), which Mehdi et al. demonstrated by site-directed mutagenesis33 Mehdi et al. demonstrated by site-directed mutagenesis
Replacing Leu313, Phe315, or Trp316 with hydrophilic residues each individually ablated cardiolipin binding in vitro; only Ala314 substitution was tolerated is structurally indispensable for phospholipid binding.

The Trp316Ser substitution (rs1801690 C→G on the plus strand) replaces the bulky, hydrophobic tryptophan at position 316 with the small, polar serine. This disrupts the integrity of the hydrophobic contact surface, reducing the protein's ability to anchor to anionic phospholipid membranes. The consequence is twofold: β2GPI with Ser316 has diminished phospholipid binding, and — critically — reduced capacity to present the cryptic epitopes on domain I that antiphospholipid antibodies (aPL) recognize. The Trp316 form (C allele, reference, ~94% of the population) binds efficiently, presents these epitopes, and can be targeted by autoantibodies that drive the coagulation cascade activation underlying APS-related thrombosis.

The Evidence

Kamboh et al. 199944 Kamboh et al. 1999
Kamboh MI et al. Genetic variation in apolipoprotein H (beta2-glycoprotein I) affects the occurrence of antiphospholipid antibodies and apolipoprotein H concentrations in systemic lupus erythematosus. Lupus. 1999;8(9):742-50 studied 194 SLE patients and found the Ser316 allele significantly underrepresented among antiphospholipid antibody-positive patients (allele frequency 3.1% vs 12.1% in aPL-negative patients, P=0.04). Among those with APS criteria, Trp316 (the common allele) was essentially universal. The variant also explained 13% of variation in plasma apoH concentrations — Ser316 carriers had higher circulating β2GPI but less phospholipid binding, consistent with the structural explanation.

Camilleri et al. 200355 Camilleri et al. 2003
Camilleri RS et al. Lack of association of beta2-glycoprotein I polymorphisms Val247Leu and Trp316Ser with antiphospholipid antibodies in patients with thrombosis and pregnancy complications. Br J Haematol. 2003;120(6):1066-72 studied 230 patients referred for aPL screening and found the Ser316 allele significantly underrepresented in aPL-negative women compared to female controls (0.020 vs 0.060, P=0.029), suggesting the Ser316 variant may protect against pregnancy complications through an anticoagulant mechanism independent of antibody production.

The TRAPS trial66 TRAPS trial
Pengo V et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood. 2018;132(13):1365-71 is the pivotal clinical landmark: rivaroxaban was terminated prematurely after 7 out of 59 patients experienced thromboembolic events (4 strokes, 3 MIs) versus zero in the warfarin arm among triple-positive APS patients. This trial, combined with mechanistic data showing that Factor Xa inhibitors do not suppress the contact activation and complement pathways implicated in APS thrombosis, has established that direct oral anticoagulants (DOACs) are contraindicated in triple-positive APS — a critically important pharmacogenomic implication for Trp316 homozygotes who develop APS.

The evidence level is rated moderate because: genetic association studies are relatively small (n < 300), findings are partially inconsistent across studies, and large prospective GWAS specifically validating this variant at genome-wide significance for APS are lacking. The functional mechanism (phospholipid binding disruption) is established, as is the clinical significance of APS itself.

Practical Implications

For the roughly 90% of people who are CC homozygous (Trp316/Trp316), the genotype represents the population-normal state — but also means their β2GPI retains full phospholipid-binding capacity and the highest potential to serve as an autoantigen if immune dysregulation develops. Key implications are anticoagulant selection if APS is diagnosed (warfarin, not DOACs), monitoring for early APS signs, and understanding that triple-positive antibody status dramatically escalates thrombotic risk.

CG heterozygotes carry one protective Ser316 allele, which may partially reduce aPL-mediated thrombotic risk but does not eliminate it. GG homozygotes (Ser316/Ser316) have approximately half the cardiolipin-binding capacity and are substantially underrepresented among APS patients in the literature — the most protected genotype.

Interactions

APOH Trp316Ser (rs1801690) acts within the same APS pathophysiology framework as APOH Val247Leu (rs1801689), a separate variant in domain V that alters the lysine-rich cluster relevant for phospholipid binding. Compound heterozygotes or co-inheritors of both APOH risk alleles may have additive effects on APS susceptibility, though combined genotype data are limited. The clinical impact of Trp316 is substantially amplified when patients are triple-positive for lupus anticoagulant, anti-cardiolipin antibodies, and anti-β2GPI antibodies simultaneously — the context in which DOAC contraindication is absolute per the TRAPS trial.

Drug Interactions

rivaroxaban contraindicated literature
apixaban contraindicated literature
dabigatran contraindicated literature

Genotype Interpretations

What each possible genotype means for this variant.

GG Reduced Phospholipid Binder Beneficial

Both copies carry the protective Ser316 allele — reduced β2GPI phospholipid binding, lowest risk for antiphospholipid autoantibody-driven thrombosis

You carry two copies of the Ser316 allele (G), the rarest common APOH genotype — present in less than 1% of most populations. The Ser316 substitution disrupts the hydrophobic binding surface of domain V in beta-2-glycoprotein I, substantially reducing the protein's capacity to anchor to anionic phospholipid membranes. Site- directed mutagenesis studies confirmed that Ser316 (replacing Trp316) abolishes cardiolipin binding in vitro. This reduced binding means your β2GPI presents fewer cryptic epitopes to the immune system and generates less substrate for antiphospholipid autoantibodies. In population studies of SLE patients, individuals with the Ser316 allele are significantly underrepresented among those who develop antiphospholipid antibodies — this genotype is associated with the lowest susceptibility to APS-related thrombosis in the APOH gene.

CG Partial Phospholipid Binder Intermediate

One protective Ser316 allele — partially reduced β2GPI phospholipid binding, modest reduction in APS autoantibody susceptibility

The heterozygous CG genotype produces a mixture of Trp316 and Ser316 β2GPI proteins. In the population-level data from Kamboh et al. (1999, PMID 10602447), the Ser316 allele was substantially less frequent among antiphospholipid antibody-positive SLE patients (3.1% vs 12.1% in aPL-negative patients), indicating that even one copy of the Ser316 allele has measurable protective effect. The Camilleri et al. 2003 study (PMID 12648080) found the Ser316 allele underrepresented in aPL-negative women vs controls, suggesting Ser316 may also protect against pregnancy complications through mechanisms beyond antibody production.

If you develop APS despite this partial protection, the same DOAC contraindication applies as for CC homozygotes — the relevant clinical question is aPL antibody status, not genotype alone.

CC Full Phospholipid Binder High Risk

Both copies carry the common Trp316 allele — full β2GPI phospholipid binding, highest potential for antiphospholipid autoantibody targeting

Beta-2-glycoprotein I (β2GPI) binds to phosphatidylserine and other anionic phospholipids through a conserved hydrophobic loop and lysine-rich cluster in domain V. The Trp316 residue contributes to this binding surface; structural studies show that its replacement with serine disrupts the hydrophobic contact, reducing phospholipid affinity. The common Trp316/Trp316 genotype means your β2GPI has intact phospholipid binding — which is normal physiology — but also means that if your immune system generates anti-β2GPI antibodies, your protein is a highly effective target for them.

The clinical significance of APS in CC homozygotes is primarily in the context of anticoagulation choice: the TRAPS trial (Pengo et al. 2018, Blood) demonstrated that rivaroxaban was associated with a significantly higher rate of thromboembolic events (including strokes and MIs) compared to warfarin in triple-positive APS patients. This applies specifically to patients who are triple-positive (lupus anticoagulant + anti-cardiolipin + anti-β2GPI antibodies).